Relmada Therapeutics, Inc.
Income Statement
| Line Item | May 2012 | Feb 2012 |
|---|---|---|
| Revenue | $400 | $6.0K |
| Cost of Revenue | $292 | $4.5K |
| Gross Profit | $108 | $1.5K |
| Gross Margin | 27.0% | 25.2% |
| Operating Expenses | ||
| Research & Development | — | — |
| SG&A Expense | $2.6K | $878 |
| Operating Income | $-2.5K | $-503 |
| Operating Margin | -620.3% | -8.3% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | — | — |
| Net Margin | — | — |
| EPS (Basic) | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 |
| Shares Outstanding (Basic) | — | — |
| Shares Outstanding (Diluted) | — | — |
| Dividends Per Share | — | — |